Bluejay Diagnostics, Inc. (BJDX) - הכנסות החברה

Intense competition in the rapid test segment is putting pressure on Bluejay Diagnostics (BJDX) gross sales revenue, which remains at 0.00. The lack of operating income and reliance on equity issuance confirm financial instability. Simultaneously, Bluejay Diagnostics is implementing eco-friendly packaging to reduce energy costs. This chart illustrates current cash flow trends, helping to assess capital sustainability.

This indicator is based on the aggregation of daily cash inflows from product sales, which allows for the neutralization of random market noise and the identification of true business activity cycles. Analyzing the sales velocity of Bluejay Diagnostics (BJDX) helps assess the company's commercial resilience amid fierce competition and risks associated with FDA approval of sepsis tests, thereby determining the entry point into the asset.